a16z Bio + Health’s Post

We are excited to announce today a new collaboration with Eli Lilly and Company to build next-generation #machinelearning models for small molecule design that save time and reduce experimentation cycles. 💻🧪✨ insitro will build advanced ML models that can accurately predict key pharmacological properties of small molecules, including their behavior in vivo. Our team will train them on Lilly’s robust, proprietary preclinical data, leveraging a rich set of in vitro and in vivo measurements from a vast array of compounds. The models will address a longstanding challenge in drug discovery: how to predict key pharmacological properties of small molecules.  ⚛️🧪 These properties include Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) which have traditionally been slow and costly to determine through experimental methods in the lab. Small molecules that reach the right tissue at the optimal concentration for the right duration result in better patient outcomes. These models:  ✅ will be trained on data from advanced molecules from decades of Lilly’s drug discovery programs, representing a world-class dataset in quality, consistency and scale ✅ will be available to insitro and our partners, Lilly and their partners, including members of Lilly TuneLab, a new platform designed to empower biotechs with cutting-edge #ML tools to transform medicine discovery ✅ could be a game-changer by giving researchers the ability to zero in on drug-like chemical structures at the earliest stages, avoiding significant wasted work and costly failures Read more in the release here: https://lnkd.in/eeZ-3Pw4